**ATTACHMENT E:**

**Expert Panel Members**

Expert Panel members were consulted in Phase I of the project (August 2012 to February 2013) and in Phase II (starting in September 2013). The following Expert Panel members have contributed to the development of the process, survey and the planned implementation process:

* **Thomas Cargiulo,** **PharmD, BCPPA,** pharmacist Board Certified in Psychiatric Pharmacy, and Medical Science and Treatment Advisor for Reckitt Benckiser Pharmaceuticals.
* **Robert L. DuPont, M.D.** President, Institute for Behavior and Health, first Director of the National Institute on Drug Abuse (1973-1978) and the second person to lead White House drug control efforts (1973-1977) for the office now known as ONDCP.
* **Sherry L. Green, J.D.** Chief Executive Officer and **Susan P. Weinstein. J.D.** Director of Congressional and Federal Affairs**,** National Alliance for Model State Drug Laws bipartisan non-profit successor to the President’s Commission on Model State Drug Laws.
* **Henrick (Rick) Harwood,** Director of Research and Program Applications ,National Association of State Alcohol and Drug Abuse Directors, Inc. (NASADAD)
* **Linda Kaplan, M.A. consultant, former** Senior Public Health Advisor at the Substance Abuse and Mental Health Services Administration (SAMHSA)
* **Kevin Lewis,** Director of Driver Programs, American Association of Motor Vehicle Administrators (AAMVA).
* **Thomas Manuel,** Senior Manager, Business Solutions and former Director of Driver Fitness, AAMVA.
* **Paul Samuels, J.D.,** Executive Director, Legal Action Center (*Phase I only*)
* **Joanne E. Thomka, J.D.** Program DirectorNational Traffic Law Center (NTLC), National District Attorneys Association
* **Brian Ursino, M.B.A .**Director of Law Enforcement**,** AAMVA, former Assistant Chief of the Washington State Patrol
* **Robert Voas**, **PhD**., Senior Research Scientist, [Alcohol, Policy, and Safety Research Center](http://www.pire.org/centers2.asp?core=38794&cms=95) Pacific Institute for Research and Evaluation (PIRE), former director of the National Highway Traffic Safety Administration's Office of Program Evaluation and Past President of the International Council on Alcohol, Drugs, and Traffic Safety.
* **Michael Wissel,** RPh. President, Alliance of States with Prescription Monitoring Programs (ASPMP) and Pharmacy Specialist, Health Regulatory Division, Bureau of Health Professions, State of Michigan. (*Note:* William Bronson, former Secretary of the ASPMP, represented that organization in Phase I. Mr. Bronson, now retired, formerly managed the Prescription Drug Monitoring Program in North Carolina).

In addition, the following representatives of interested Federal agencies have also contributed to the development of the study and reviewed the survey materials as ex-officio and unpaid Expert Panelists.

* **Heidi Coleman, J.D.,** Chief, Impaired Driving Division, National Highway Traffic Safety Administration.
* **Augusto (Augie) Diana, Ph.D.,** (former) Contract Officer’s Representative (COR) on this contract and Prevention Research Branch, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse (NIDA), National Institutes of Health.
* **Ralph Hingson, Sc.D., M.P.H.,** Director, Division of Epidemiology and Prevention Research, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health.
* **Terry S. Zobeck, Ph.D.,** Associate Director for the Office of Research/Data Analysis (ORDA), Office of National Drug Control Policy (ONDCP), Executive Office of the President.